Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06677151

NPA-OSA Device Tolerability, Usability and Acclimation Clinical Study in Adult Obstructive Sleep Apnea (OSA) Patients

This pilot study is being done to determine if the nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device can be used in the treatment of OSA in adults. The researchers think that the NPA-OSA device will reduce the number of apneas.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Michigan Medicine, Ann Arbor, Michigan, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capacity and willingness to sign consent
  • Patient willingness to commit to and complete study over a 30-day time period
  • Confirmed diagnosis of moderate to severe OSA (AHI >= 15)
  • OSA caused by upper airway obstruction
  • CPAP non-compliant where CPAP compliance is defined as using CPAP for at least 4 hours a night for at least 70% of nights or interest in an alternative sleep apnea therapy
  • Adequate manual dexterity to demonstrate ability to self-insert and remove device

Exclusion criteria

  • Within 3 months of initiating CPAP use, and actively using CPAP
  • Supraglottic airway collapse
  • Distal airway stenosis
  • Tracheobronchomalacia
  • Currently pregnant
  • Active COVID-19 infection
  • Need for anticoagulative therapy
  • Severe nasal allergies
  • Bleeding disorder
  • More than mild elevation of End-tidal carbon dioxide (ETCO2) or total carbon dioxide (TCO2) values >60 mmHg for >10% of sleep time
  • Restrictive thoracic disorders
  • Silicone, lidocaine, neosynephrine allergy
  • Recurrent epistaxis
  • Uncontrolled or serious illness, included but not limited to: severe breathing disorders including hypercapnic respiratory failure, respiratory muscle weakness, bullous lung disease (as seen in some types of emphysema), bypassed upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease (including heart failure); or pathologically low blood pressure

Treatment and study plan

nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device

Device

The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.

Primary outcomes

  1. Change in severity of apnea hypopnea index (AHI)

    Time frame: Baseline (day 0), 30 days

    The AHI is calculated by dividing the number of apnea events by the number of hours of sleep.

Study contacts

Contact information is provided by the study sponsor or research team.

Louise M O'Brien, PhD

CONTACT

[email protected]

734 647-9064

Zahra Nourmohammadi, PhD

CONTACT

[email protected]

734 936-9816

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • Wallace H Coulter Center for Translational Research

Registry information

Official study title

NPA-OSA Device Tolerability, Usability and Acclimation Clinical Study in Continuous Positive Airway Pressure (CPAP) Resistant Adult OSA Patients

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 6, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.